Claims for Patent: 8,242,095

Summary for Patent: 8,242,095

Title:	In vivo and ex vivo gene transfer into renal tissue using gutless adenovirus vectors
Abstract:	A method for treating a renal disease in a subject is disclosed. The method includes administering into a kidney of the subject with an effective amount of a gutless adenoviral vector containing a polynucleotide encoding a therapeutic agent. The gutless adenoviral vector contains the nucleotide sequence of SEQ ID NO:13 or SEQ ID NO:15 and expresses the therapeutic agent in a kidney tissue of the subject.
Inventor(s):	Sehgal; Lakshman R. (Monarch Beach, CA), Wong; Jonathan (Palo Alto, CA)
Assignee:	BIOVEC, LLC (Chicago, IL)
Application Number:	12/778,340
Patent Claims:	1. A method for modulating an immune response in a kidney allograft recipient, comprising: perfusing a kidney harvested from an organ donor with an effective amount of a gutless adenovirus carrying a nucleotide sequence encoding an immune modulator and a regulatory element operably linked to said nucleotide sequence; and transplanting the perfused kidney into a subject in need of a kidney transplant, wherein said gutless adenovirus expresses said immune modulator in said kidney, wherein said immune modulator is indoleamine dioxygenase, and wherein the gutless adenovirus is administered in an amount sufficient for reducing plasma creatinin levels, reducing tissue damage, reducing macrophage influx or reducing a fibrotic response in said recipient following transplantation, as compared to the amount observed in a control organ that received only saline. 2. The method of claim 1, wherein said regulatory element comprises a constitutive promoter or a renal-specific regulatory element. 3. The method of claim 2, wherein said renal-specific regulatory element is a renal-specific promoter. 4. The method of claim 3, wherein said renal-specific promoter is selected from the group consisting of high-capacity (type 2) Na.sup.+/glucose cotransporter gene (Sglt2)promoter, Ksp-cadherin promoter, ClC-K1 chloride channel gene promoter, uromodulin promoter, Nkcc2/Slc12a1 gene promoter, and the p1 promoter of the parathyroid hormone (PTH)/PTH-related peptide receptor gene. 5. The method of claim 1, wherein said gutless adenovirus vector comprises a stuffer comprising the nucleotide sequence of SEQ ID NO:13 or SEQ ID NO:15. 6. The method of claim 1, wherein said kidney is perfused with said gutless virus for a period of 10-120 minutes. 7. The method of claim 1, wherein said gutless adenovirus is suspended at a concentration of 10.sup.9-10.sup.12 particles/ml. 8. A method for modulating an immune response in a kidney allograft recipient, comprising: perfusing a kidney harvested from an organ donor with an effective amount of a gutless adenovirus carrying a nucleotide sequence encoding an immune modulator and a regulatory element operably linked to said nucleotide sequence; and transplanting the perfused kidney into a subject in need of a kidney transplant, wherein said gutless adenovirus expresses said immune modulator in said kidney, wherein the gutless adenovirus is administered in an amount sufficient for reducing plasma creatinin levels, reducing tissue damage, reducing macrophage influx or reducing a fibrotic response in said recipient following transplantation, as compared to the amount observed in a control organ that received only saline, and wherein said gutless adenovirus vector comprises the nucleotide sequence of SEQ ID NO:21 or SEQ ID NO:22.

Details for Patent 8,242,095

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2022-12-02